Jul 21, 2026 08:03AM
Jul 21, 2026 08:00AM
Jul 13, 2026 09:01AM
Jul 13, 2026 09:00AM
Jun 30, 2026 08:00PM
Jun 30, 2026 08:00PM
Jun 24, 2026 08:01AM Cadrenal CAD-1005 trial selected for oral presentation at ISTH 2026
Jun 24, 2026 08:00AM
Jun 18, 2026 09:01AM
Jun 18, 2026 09:00AM
Jun 15, 2026 08:30AM
Jun 15, 2026 08:30AM
Jun 3, 2026 09:02AM
Jun 3, 2026 09:00AM Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
May 19, 2026 04:30PM
May 7, 2026 08:30AM
May 7, 2026 08:30AM
Apr 30, 2026 08:30AM
Apr 30, 2026 08:30AM
Mar 31, 2026 08:45AM
Mar 31, 2026 08:45AM Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Mar 12, 2026 08:00AM
Mar 2, 2026 08:01AM
Mar 2, 2026 08:00AM
Feb 24, 2026 08:30AM
Feb 24, 2026 08:30AM
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic S
Dec 11, 2025 08:05AM
Dec 11, 2025 08:05AM
Aug 5, 2025 06:01AM
Aug 5, 2025 06:00AM
May 8, 2025 08:00AM
Mar 13, 2025 04:05PM
Jan 9, 2025 08:44AM Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Dec 31, 2024 08:00AM
Nov 12, 2024 09:00AM
Nov 7, 2024 09:00AM
Aug 22, 2024 09:03AM
Aug 22, 2024 09:00AM
Aug 20, 2024 09:00AM
Aug 14, 2024 09:00AM Cadrenal Therapeutics to Present at Upcoming Investor Conferences
Aug 7, 2024 04:05PM
Aug 6, 2024 09:00AM
Jul 17, 2024 09:00AM
Jun 11, 2024 04:15PM
Jun 3, 2024 09:00AM
May 23, 2024 09:00AM
May 9, 2024 09:00AM Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
Apr 11, 2024 04:30PM

326,853 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All